Imatinib
- TRADE NAMES: Gleevec (Novartis); Glivec
- INDICATIONS: Chronic myeloid leukemia
- CLASS: Antineoplastic / anticancer agent (see also Immune checkpoint inhibitor), Biologic, CYP3A4 inhibitor, Tyrosine kinase inhibitor
- HALF-LIFE: 18 hours
Acetaminophen, Amlodipine, Anisindione, Anticoagulants, Aprepitant, Atorvastatin, Barbiturates, Benzodiazepines, Butabarbital, Carbamazepine, Chlordiazepoxide, Clarithromycin, Clonazepam, Clorazepate, Corticosteroids, Cyclosporine, Dexamethasone, Diazepam, Dicumarol, Efavirenz, Erythromycin, Ethotoin, Felodipine, Flurazepam, Fluvastatin, Fosphenytoin, Isradipine, Itraconazole, Ketoconazole, Lorazepam, Lovastatin, Mephenytoin, Mephobarbital, Midazolam, Mifepristone, Neratinib, Nicardipine, Nifedipine, Nimodipine, Nisoldipine, Olaparib, Oxazepam, Oxcarbazepine, Pentobarbital, Phenobarbital, Phenytoin, Pimozide, Pravastatin, Primidone, Quazepam, Rifampin, Rifapentine, Safinamide, Secobarbital, Simvastatin, St John's Wort, Tafamidis meglumine, Temazepam, Voriconazole, Warfarin
PREGNANCY CATEGORY: D
See adverse reactions attributed to class:
Antineoplastic / anticancer agent (see also Immune checkpoint inhibitor)
Acneiform eruption / acneiform dermatitis / acneiform rash
(2018): Hwang A+, J Oncol Pharm Pract Jan, Epub ahead of print
(2011): Demirci U+, J Oncol Pharm Pract 17(3), 285
(2006): Martin JM+, J Eur Acad Dermatol Venereol 20(10), 1368
Acute febrile neutrophilic dermatosis (Sweet's syndrome)
(2018): Biswal SG+, Indian J Dermatol 63(1), 41
(2017): Penn EH+, Cutis 99(3), 189 [REVIEW] (passim)
(2016): Lupu I+, J Med Life 9(1), 19 [REVIEW]
(2005): Ayirookuzhi SJ+, Arch Dermatol 141(3), 368
Acute generalized exanthematous pustulosis (AGEP)
(2016): Lupu I+, J Med Life 9(1), 19 [REVIEW]
(2015): Scott AD+, Clin Exp Dermatol 40(8), 926
(2014): Pretel-Irazabal M+, Actas Dermosifiliogr 105(7), 655
(2006): Nelson RP Jr+, Ann Allergy Asthma Immunol 97(2), 216
(2006): Scheinfeld N, J Drugs Dermatol 5(3), 228 [REVIEW]
(2002): Schwarz M+, Eur J Haematol 69(4), 254 (2 cases)
(2001): Brouard MC+, Dermatology 203(1), 57
Cutaneous adverse reaction (includes severe cutaneous adverse drug reaction (SCAR))
(2020): Phukan A+, Ann Hematol Oct, Online ahead of print71%
Cutaneous toxicity / skin toxicity
(2017): Ransohoff JD+, Clin Lymphoma Myeloma Leuk 17(12), 834 [REVIEW]
(2016): Ben Ami E+, Expert Opin Drug Saf 15(4), 571 [REVIEW]30–44%
(2016): Breccia M+, Expert Opin Drug Saf 15(4), 525 [REVIEW]
(2016): Desar IM+, Anticancer Drugs 27(6), 576
(2015): Macdonald JB+, J Am Acad Dermatol 72(2), 203 [REVIEW]
(2013): Brazzelli V+, J Eur Acad Dermatol Venereol 27(12), 1471 [REVIEW]
(2013): Trabelsi S+, Ann Biol Clin (Paris) (French) 71(2), 203
(2009): Mauro MJ+, Best Pract Res Clin Haematol 22(3), 409 [REVIEW]
(2003): Ugurel S+, Br J Cancer 88(8), 1157
DRESS syndrome
(2021): Park H+, Case Rep Oncol 14(3), 1548-1554 (1 case / female)
(2019): Zgolli F+, Curr Drug Saf Jan, Epub ahead of print1 case (grade 3+)
(2017): Vatel O+, Leuk Lymphoma 58(2), 473
(2008): Goldman J+, Ann Dermatol Venereol 135 (5), 393
(2006): Le Nouail P+, Ann Dermatol Venereol 133(8-9 Pt 1), 686
Edema / fluid retention (see also peripheral edema) <5%
(2021): Amouei A+, Int J Hematol Oncol Stem Cell Res 15(2), 114-131 [REVIEW]
(2020): Phukan A+, Ann Hematol Oct, Online ahead of print62% (3% grade 3/4)
(2019): Abou Dalle I+, Cancer Med Sep, Epub ahead of print13%
(2019): Zhang LQ+, Zhonghua Er Ke Za Zhi 57(2), 11317%
(2018): Fu Y+, Thorac Cancer Mar, Epub ahead of print39%
(2016): Ault PS+, J Adv Pract Oncol 7(2), 16062%
(2016): Ben Ami E+, Expert Opin Drug Saf 15(4), 571 [REVIEW]40–74%
(2016): Breccia M+, Expert Opin Drug Saf 15(4), 525 [REVIEW]60%
(2016): Dervis E+, Eur J Dermatol 26(2), 133
(2016): Ghunawat S+, Indian J Dermatol Venereol Leprol 82(4), 409 (passim)
(2016): Inayat F+, Anticancer Res 36(11), 6201>30% (passim)
(2016): Turhan AG, Leuk Lymphoma 57(11), 2731 (passim)
(2016): Wasif K+, Cureus 8(10), e848 (passim)
(2016): Yu L+, Zhonghua Xue Ye Xue Za Zhi (Chinese) 37(7), 55451%
(2015): Brummendorf TH+, Br J Haematol 168(1), 69
(2014): Hsu CC+, Anticancer Res 34(9), 5029
(2014): Linga VG+, South Asian J Cancer 3(4), 20339%
(2014): Pretel-Irazabal M+, Actas Dermosifiliogr 105(7), 655
(2014): Serrano C+, Ther Adv Med Oncol 6(3), 115 [REVIEW]
(2014): Thota NK+, Indian J Cancer 51(1), 580%
(2013): Matti BF+, Turk J Haematol 30(4), 38752%
(2013): Zhou L+, Zhonghua Xue Ye Xue Za Zhi (Chinese) 34(2), 93
(2012): Cortes JE+, J Clin Oncol 30(28), 3486
(2012): Kantarjian HM+, Blood 119(5), 1123
(2012): Radich JP+, Blood 120(19), 389850%
(2011): Imagawa J+, Rinsho Ketsueki 52(7), 546
(2011): Khanna D+, Arthritis Rheum 63(11), 3540 (lower extremity)
(2010): Wei G+, J Hematol Oncol 3, 47 [REVIEW]
(2006): Scheinfeld N, J Drugs Dermatol 5(3), 228 [REVIEW]
(2005): Modi S+, Breast Cancer Res 90(2), 15738%
(2005): Severino G+, Ann Pharmacother 39(1), 162
(2004): Curran MP+, BioDrugs 18(3), 207 [REVIEW]
(2003): Prescrire Int 12(64), 49<5%
(2003): Shimazaki C+, Leukemia 17(4), 804
(2003): Valeyrie L+, J Am Acad Dermatol 48(2), 201 (35 cases)
(2002): Dagher R+, Clin Cancer Res 8(10), 3034
(2002): Demetri GD+, N Engl J Med 347(7), 472
(2002): Pindolia VK+, Pharmacotherapy 22(10), 1249 [REVIEW]
(2002): Tefferi A+, Blood 99(10), 3854
(2001): van Oosterom AT+, Lancet 358(9291), 1421
Erythema <10%
(2016): Ben Ami E+, Expert Opin Drug Saf 15(4), 571 [REVIEW]
(2006): Scheinfeld N, J Drugs Dermatol 5(3), 228 [REVIEW]
(2005): Sugito M+, Rinsho Ketsueki 46(11), 1226
(2003): Duncan E+, Br J Haematol 122(1), 1
(2003): Pasmatzi E+, Acta Derm Venereol 83(5), 391
Erythema multiforme
(2017): Penn EH+, Cutis 99(3), 189 [REVIEW] (passim)
(2016): Ben Ami E+, Expert Opin Drug Saf 15(4), 571 [REVIEW]
Erythroderma
(2018): Lunge S+, J Assoc Physicians India 66(12), 79 (1 case)
(2013): Verma R+, Indian J Pharmacol 45(6), 634
(2007): Vano-Galvan S+, Eur J Dermatol 17(6), 538
(2006): Oztas P+, Acta Derm Venereol 86(2), 174
Exanthems
(2016): Ben Ami E+, Expert Opin Drug Saf 15(4), 571 [REVIEW]
(2016): Ghunawat S+, Indian J Dermatol Venereol Leprol 82(4), 409 (passim)
(2016): Lupu I+, J Med Life 9(1), 19 [REVIEW]
(2010): Hwang JE+, BMC Cancer 10, 438
(2006): Nelson RP Jr+, Ann Allergy Asthma Immunol 97(2), 216
(2006): Scheinfeld N, J Drugs Dermatol 5(3), 228 [REVIEW]
(2004): Park MA+, Allergy Asthma Proc 25(5), 345 [REVIEW]
(2003): Dogra S+, Natl Med J India 16(5), 285
(2002): Dagher R+, Clin Cancer Res 8(10), 3034
Exfoliative dermatitis
(2017): Penn EH+, Cutis 99(3), 189 [REVIEW] (passim)
(2010): Hwang JE+, BMC Cancer 10, 438
(2006): Nelson RP Jr+, Ann Allergy Asthma Immunol 97(2), 216
(2003): Tanvetyanon T+, Ann Pharmacother 37(12), 1818
Facial edema <10%
(2017): Penn EH+, Cutis 99(3), 189 [REVIEW] (passim)
(2014): Thota NK+, Indian J Cancer 51(1), 5
(2011): Khanna D+, Arthritis Rheum 63(11), 3540
Hand–foot syndrome (palmar–plantar erythrodysesthesia)
(2012): Kumar P+, J Postgrad Med 58(4), 331
(2010): Dugan E+, Anticancer Res 30 (4), 1251 (with capecitabine)
(2008): Battistella M+, Arch Dermatol 144(10), 1400
Hypomelanosis
(2013): Sibaud V+, Ann Dermatol Venereol 140(4), 266
(2006): Brazzelli V+, Pediatr Dermatol 23(2), 175
(2005): McPartlin S+, Br J Haematol 129(4), 448
(2004): Grossman WJ+, J Pediatr Hematol Oncol 26(3), 214
(2003): Tsao AS+, Cancer 98(11), 2483
Lichen planus
(2011): Sudha R+, Indian J Dermatol 56(3), 351
(2009): Kaliyadan F+, Indian J Dermatol Venereol Leprol 75(5), 527
(2009): Martinez de Lagran Z+, Med Clin (Barc) 133(20), 805
(2008): Wahiduzzaman M+, Dermatol Online J 14(12), 14
(2004): Roux C+, Ann Dermatol Venereol 131(6-7 Pt I), 571
Lichenoid eruption
(2017): Penn EH+, Cutis 99(3), 189 [REVIEW]
(2017): Vigarios E+, Support Care Cancer 25(5), 1713 [REVIEW]
(2016): Lupu I+, J Med Life 9(1), 19 [REVIEW]
(2014): De D+, Indian J Dermatol Venereol Leprol 80(1), 93
(2014): Pretel-Irazabal M+, Actas Dermosifiliogr 105(7), 655
(2013): Ghosh SK, Indian J Dermatol 58(5), 388 [REVIEW]
(2008): Wahiduzzaman M+, Dermatol Online J 14(12), 14
(2007): Chan CY+, Dermatol Online J 13(2), 29
(2006): Dalmau J+, Br J Dermatol 154(6), 1213
(2006): Scheinfeld N, J Drugs Dermatol 5(3), 228 [REVIEW]
(2005): Prabhash K+, Indian J Derm, Venereol Leprol 71(4), 287
(2002): Lim DS+, Dermatology 205(2), 169-71 (1 case / female)
Maculopapular rash / morbilliform rash
(2018): Lunge S+, J Assoc Physicians India 66(12), 79 (1 case)
Mycosis fungoides
(2016): Lupu I+, J Med Life 9(1), 19 [REVIEW]
(2006): Scheinfeld N, J Drugs Dermatol 5(3), 228 [REVIEW]
Neutrophilic eccrine hidradenitis
(2016): Lupu I+, J Med Life 9(1), 19 [REVIEW]
(2006): Scheinfeld N, J Drugs Dermatol 5(3), 228 [REVIEW]
(2005): Dib EG+, Leuk Res 29(2), 233
Panniculitis
(2016): Lupu I+, J Med Life 9(1), 19 [REVIEW]
(2011): de Masson A+, Ann Dermatol Venereol 138(2), 135
(2003): Ugurel S+, Br J Dermatol 149, 678
Pemphigus
(2020): Marion M+, Dermatol Ther Jun, Online ahead of print (1 case / male)
(2018): Sood A+, Indian Dermatol Online J 9(5), 331-333 (1 case / female)
Peripheral edema (see also edema) <10%
(2016): Breccia M+, Expert Opin Drug Saf 15(4), 525 [REVIEW]
(2015): Gambacorti-Passerini C+, Am J Hematol 89(10), 94712%
(2015): Kekale M+, Patient Prefer Adherence 9, 173375%
(2014): Thota NK+, Indian J Cancer 51(1), 5
(2013): Kanda T+, Int J Clin Oncol 18(1), 3837%
Photosensitivity <10%
(2017): Penn EH+, Cutis 99(3), 189 [REVIEW] (passim)
(2016): Lupu I+, J Med Life 9(1), 19 [REVIEW]
(2003): Rousselot P+, Br J Haematol 120(6), 1091
Pigmentation
(2018): Di Tullio F+, Int J Dermatol Feb, Epub ahead of print [REVIEW]
(2018): Fu Y+, Thorac Cancer Mar, Epub ahead of print56%
(2017): Kok WL+, J Dermatolog Treat 28(8), 762
(2017): Vigarios E+, Support Care Cancer 25(5), 1713 [REVIEW]
(2016): Dervis E+, Eur J Dermatol 26(2), 133
(2016): Ghunawat S+, Indian J Dermatol Venereol Leprol 82(4), 409 (5 cases)
(2016): Lupu I+, J Med Life 9(1), 19 [REVIEW]
(2016): Yu L+, Zhonghua Xue Ye Xue Za Zhi (Chinese) 37(7), 55422%
(2014): Linga VG+, South Asian J Cancer 3(4), 20354%
(2014): Thota NK+, Indian J Cancer 51(1), 560%
(2013): Sibaud V+, Ann Dermatol Venereol (French) 140(4), 266 [REVIEW]
(2012): Resende RG+, J Craniomaxillofac Surg 40(5), e140
(2006): Scheinfeld N, J Drugs Dermatol 5(3), 228 [REVIEW]
(2004): Arora B+, Ann Oncol 15(2), 358
Pityriasis rosea
(2011): Cho AY+, Ann Dermatol 23(Suppl 3), S360
(2006): Scheinfeld N, J Drugs Dermatol 5(3), 228 [REVIEW]
(2005): Brazzelli V+, J Am Acad Dermatol 53(5 Suppl 1), S240
(2003): Pasmatzi E+, Acta Derm Venereol 83(5), 391
(2002): Konstantopoulos K+, Dermatology 205(2), 172
Pruritus (itching) 6–10%
(2016): Ben Ami E+, Expert Opin Drug Saf 15(4), 571 [REVIEW]
(2013): Ensslin CJ+, J Am Acad Dermatol 69(5), 708 [REVIEW]10%
(2003): Valeyrie L+, J Am Acad Dermatol 48(2), 201 (22 cases)
Pseudolymphoma
(2006): Scheinfeld N, J Drugs Dermatol 5(3), 228 [REVIEW]
(2005): Jardin F+, Lancet Oncol 6(9), 728
(2003): Clark SH+, J Cutan Pathol 30(4), 279
Psoriasiform eruption (see also psoriasis)
(2018): Shi CR+, Am J Hematol 93(3), 467-468 (1 case / female)
Psoriasis
(2017): Penn EH+, Cutis 99(3), 189 [REVIEW] (passim)
(2014): Pretel-Irazabal M+, Actas Dermosifiliogr 105(7), 655
(2005): Shimizu K+, Rinsho Ketsueki 46(10), 1152
Pyoderma gangrenosum
(2021): Faraci AG+, Indian J Dermatol Venereol Leprol 87(5), 704-706 (1 case / female)
(2013): Pinato DJ+, J Postgrad Med 59(3), 244
Rash 32–39%
(2019): Zhang LQ+, Zhonghua Er Ke Za Zhi (Chinese) 57(2), 1133%
(2016): Ault PS+, J Adv Pract Oncol 7(2), 16040%
(2016): Breccia M+, Expert Opin Drug Saf 15(4), 525 [REVIEW]40%
(2016): Dervis E+, Eur J Dermatol 26(2), 133
(2016): Gomez-Almaguer D+, Hematology 21(7), 411 (4 cases) (with nilotinib)
(2016): Inayat F+, Anticancer Res 36(11), 6201>30% (passim)
(2016): Lipton JH+, Lancet Oncol 17(5), 6121% (grade 3 or 4)
(2016): Lupu I+, J Med Life 9(1), 19 [REVIEW]
(2016): Turhan AG, Leuk Lymphoma 57(11), 2731 (passim)
(2016): Wasif K+, Cureus 8(10), e848 (passim)
(2016): Yu L+, Zhonghua Xue Ye Xue Za Zhi (Chinese) 37(7), 55411%
(2015): Kekale M+, Patient Prefer Adherence 9, 173332%
(2014): Linga VG+, South Asian J Cancer 3(4), 20315%
(2013): Kanda T+, Int J Clin Oncol 18(1), 3837%
(2013): Kang YK+, Cancer Chemother Pharmacol 71(1), 438%
(2012): Kantarjian HM+, Blood 119(5), 1123
(2012): Radich JP+, Blood 120(19), 389828%
(2011): Khanna D+, Arthritis Rheum 63(11), 3540 (generalized)
(2009): Basso FG+, Support Care Cancer 17(4), 465
(2009): Cortes JE+, J Clin Oncol 27(28), 4754
(2005): Breccia M+, Eur J Haematol 74(2), 121
(2005): Modi S+, Breast Cancer Res Treat 90(2), 15725%
(2005): Severino G+, Ann Pharmacother 39(1), 162
(2004): Curran MP+, BioDrugs 18(3), 207 [REVIEW]
(2003): Valeyrie L+, J Am Acad Dermatol 48(2), 201 (36 cases)
(2003): Verweij J+, Eur J Cancer 39(14), 200669%
(2001): van Oosterom+, Lancet 358(9291), 1421
Squamous cell carcinoma
(2016): Inayat F+, Anticancer Res 36(11), 6201
(2003): Baskaynak G+, Eur J Haematol 70(4), 231
Stevens-Johnson syndrome
(2018): Fakoya AOJ+, Open Access Maced J Med Sci 6(4), 730 [REVIEW]
(2018): Ng CY+, J Immunol Res Jan, Epub [REVIEW]
(2017): Penn EH+, Cutis 99(3), 189 [REVIEW] (passim)
(2016): Ben Ami E+, Expert Opin Drug Saf 15(4), 571 [REVIEW]
(2016): Lupu I+, J Med Life 9(1), 19 [REVIEW]
(2014): Bois E+, J Oncol Pharm Pract 20(6), 476
(2013): Jha P+, BMJ Case Rep 2013
(2012): Lamchahab M+, Ann Dermatol Venereol 139(12), 828
(2009): Hsieh HJ+, Chemotherapy 55(4), 197 (with allopurinol)
(2006): Nelson RP Jr+, Ann Allergy Asthma Immunol 97(2), 216
(2006): Scheinfeld N, J Drugs Dermatol 5(3), 228 [REVIEW]
(2005): Pavithran K+, Indian J Dermatol Venereol Leprol 71(4), 288 [REVIEW]
(2005): Severino G+, Ann Pharmacother 39(1), 162 (with lansoprazole)
(2002): Hsiao LT+, Br J Haematol 117(3), 620
(2002): Vidal D+, Br J Haematol 119(1), 274
Toxic epidermal necrolysis (Lyell's syndrome)
(2018): Ng CY+, J Immunol Res Jan, Epub [REVIEW]
(2006): Scheinfeld N, J Drugs Dermatol 5(3), 228 [REVIEW]
Urticaria / hives
(2017): Penn EH+, Cutis 99(3), 189 [REVIEW] (passim)
(2016): Lupu I+, J Med Life 9(1), 19 [REVIEW]
(2006): Nelson RP Jr+, Ann Allergy Asthma Immunol 97(2), 216
Vasculitis (angiitis) / cutaneous vasculitis (angiitis)
(2016): Lupu I+, J Med Life 9(1), 19 [REVIEW]
(2006): Scheinfeld N, J Drugs Dermatol 5(3), 228 [REVIEW]
Xerosis / xeroderma (see also dry skin) <10%
(2017): Penn EH+, Cutis 99(3), 189 [REVIEW] (passim)
(2016): Dervis E+, Eur J Dermatol 26(2), 133
Alopecia / hair loss 10–15%
(2017): Penn EH+, Cutis 99(3), 189 [REVIEW] (passim)
(2016): Dervis E+, Eur J Dermatol 26(2), 133
Follicular mucinosis
(2006): Scheinfeld N, J Drugs Dermatol 5(3), 228 [REVIEW]
(2004): Yanagi T+, Br J Dermatol 151(6), 1276
Nail dystrophy
(2017): Benabbes M+, Ann Pharm Fr 75(3), 172
(2006): Deguchi N+, Br J Dermatol 154(6), 1216
Nail pigmentation
(2018): Di Tullio F+, Int J Dermatol Feb, Epub ahead of print [REVIEW]
(2006): Prabhash K+, Indian J Dermatol Venereol Leprol 72(1), 63
Aphthous stomatitis / aphthous ulcer / aphtha (aphthae)
(2016): Dervis E+, Eur J Dermatol 26(2), 133
Mucocutaneous eruption (includes fixed eruption)
(2014): Grasso V+, G Ital Dermatol Venereol 149(3), 317 [REVIEW]
Mucositis
(2015): Loue C+, J Clin Pharm Ther Jun, Epub ahead of print (2 cases) (with methotrexate)
(2014): Thota NK+, Indian J Cancer 51(1), 515%
Oral lichenoid eruption
(2008): Wahiduzzaman M+, Dermatol Online J 14(12), 14
(2004): Ena P+, J Dermatol Treatment 15(4), 253
(2002): Lim DS+, Dermatology 205(2), 169
Oral pigmentation
(2018): Di Tullio F+, Int J Dermatol Feb, Epub ahead of print [REVIEW]
(2012): Resende RG+, J Craniomaxillofac Surg 40(5), e140
(2012): Yu YH+, Tex Dent J 129(8), 764
(2011): Mattsson U+, Oral Surg Oral Med Oral Pathol Oral Radiol Endod 111(5), e12
Oral ulceration (see also aphthous stomatitis / aphthous ulcer / aphtha)
(2014): Linga VG+, South Asian J Cancer 3(4), 2039%
(2014): Thota NK+, Indian J Cancer 51(1), 515%
(2009): Basso FG+, Support Care Cancer 17(4), 465
Cardiac failure
(2022): Li Z+, J Coll Physicians Surg Pak 32(1), 114-116 (1 case / male)
(2011): Toubert ME+, Thyroid 21(4), 451 (fatal)
(with sorafenib)
Cardiotoxicity
(2016): Chen ZI+, Mol Clin Oncol 4(5), 675 [REVIEW]
(2006): Kerkela R+, Nat Med 12(8), 908
Congestive heart failure
(2016): Ben Ami E+, Expert Opin Drug Saf 15(4), 571 [REVIEW]<1%
(2016): Breccia M+, Expert Opin Drug Saf 15(4), 525 [REVIEW]
Pericardial effusion
(2021): Su PY+, J Infect Chemother Oct, Online ahead of print (1 case / male)
(2019): Terry C+, BMJ Case Rep 12(9), e229975 (1 case)
(2016): Ben Ami E+, Expert Opin Drug Saf 15(4), 571 [REVIEW]
Pulmonary edema / cardiogenic pulmonary edema
(2016): Ben Ami E+, Expert Opin Drug Saf 15(4), 571 [REVIEW]
QT interval prolonged / QT prolongation
(2016): Breccia M+, Expert Opin Drug Saf 15(4), 525 [REVIEW]
(2012): Radich JP+, Blood 120(19), 38981%
Anorexia
(2014): Thota NK+, Indian J Cancer 51(1), 526%
(2013): Kang YK+, Cancer Chemother Pharmacol 71(1), 43
(2012): Radich JP+, Blood 120(19), 389810%
(2010): Dugan E+, Anticancer Res 30 (4), 1251 (with capecitabine)
Depression 15%
(2015): Kekale M+, Patient Prefer Adherence 9, 173321%
(2003): Prescrire Int 12(68), 216
Fever (pyrexia) (includes hyperpyrexia) 13–41%
(2019): Zhang LQ+, Zhonghua Er Ke Za Zhi 57(2), 1136%
(2016): Breccia M+, Expert Opin Drug Saf 15(4), 525 [REVIEW]
(2014): Gambacorti-Passerini C+, Am J Hematol 89(10), 94712%
Headache 19–37%
(2020): Phukan A+, Ann Hematol Oct, Online ahead of print5%
(2016): Ault PS+, J Adv Pract Oncol 7(2), 16037%
(2016): Breccia M+, Expert Opin Drug Saf 15(4), 525 [REVIEW]37%
(2016): Wasif K+, Cureus 8(10), e848 (passim)
(2012): Radich JP+, Blood 120(19), 389819%
Pain
(2019): Zhang LQ+, Zhonghua Er Ke Za Zhi 57(2), 11323%
(2015): Kekale M+, Patient Prefer Adherence 9, 173319%
Subdural hemorrhage
(2015): Frost AE+, J Heart Lung Transplant 34(11), 1366 (6 cases)
(2013): Hoeper MM+, Circulation 127(10), 1128
Tremor
(2019): Obeidat K+, Case Rep Oncol 12(3), 913 (1 case)
(2015): Jang BH+, Korean J Gastroenterol 65(6), 366 (1 case)
(2011): Cameron S+, Case Rep Oncol 4(3), 505 (1 case)
Vertigo / dizziness
(2013): Kim KA+, Clin Ther 35(10), 1595 (mild / 1 case)
(2010): Dugan E+, Anticancer Res 30 (4), 1251 (with capecitabine)
Aspartate aminotransferase (AST) increased
(2016): Ben Ami E+, Expert Opin Drug Saf 15(4), 571 [REVIEW]
Creatine phosphokinase (CPK) / creatine kinase increased (hyperCKemia)
(2014): Bauer S+, Br J Cancer 110(5), 1155 (with panobinostat)
(2014): Gambacorti-Passerini C+, Am J Hematol 89(10), 94720%
Gynecomastia
(2016): Breccia M+, Expert Opin Drug Saf 15(4), 525 [REVIEW]
(2011): Liu H+, BMC Gastroenterol 11, 116 (6 cases)
(2005): Kim H+, J Korean Med Sci 20(3), 512 (unilateral)
(2003): Gambacorti-Passerini C+, Lancet 361(9373), 1954
Hypophosphatemia
(2020): Ivanovic-Zuvic D+, Rev Med Chil (Spanish) 148(3), 404-408 (1 case / male)
(2019): Sakurada H+, Gan To Kagaku Ryoho (Japanese) 46(5), 891-894 (12 cases)
(2015): Blay JY+, Lancet Oncol 16(5), 5506% (grade 3 or 4)
(2013): Zhou L+, Zhonghua Xue Ye Xue Za Zhi (Chinese) 34(2), 93
(2007): Osorio S+, Am J Hematol 82(5), 394-539%
(2006): Berman E+, N Engl J Med 354(19), 2006-13
Hypothyroidism
(2014): Fallahi P+, Expert Opin Drug Saf 13(6), 723 [REVIEW]25%
(2012): Zygulska AL+, Endokrynol Pol 63(4), 302
Inappropriate secretion of antidiuretic hormone (SIADH)
(2008): Liapis K+, Ann Pharmacother 42 (12), 1882
Porphyria cutanea tarda
(2016): Lupu I+, J Med Life 9(1), 19 [REVIEW]
(2004): Breccia M+, Leukemia 18(1), 182
(2003): Ho AY+, Br J Haematol 121(2), 375
Pseudoporphyria
(2016): Batrani M+, Indian J Dermatol Venereol Leprol 82(6), 727
(2016): Lupu I+, J Med Life 9(1), 19 [REVIEW]
(2014): Mahon C+, Pediatr Dermatol 31(5), 603 (2 cases)
(2010): Berghoff AT+, J Am Acad Dermatol 63(1), e14
(2009): Timmer-de Mik L+, Clin Exp Dermatol 34 (6), 705
Weight gain 5–32%
(2016): Yu L+, Zhonghua Xue Ye Xue Za Zhi (Chinese) 37(7), 55413%
(2014): Linga VG+, South Asian J Cancer 3(4), 20339%
(2013): Matti BF+, Turk J Haematol 30(4), 38752%
Abdominal pain
(2016): Breccia M+, Expert Opin Drug Saf 15(4), 525 [REVIEW]37%
(2016): Inayat F+, Anticancer Res 36(11), 6201>30% (passim)
(2016): Wasif K+, Cureus 8(10), e848 (passim)
(2015): Blay JY+, Lancet Oncol 16(5), 5504% (grade 3 or 4)
(2015): Loue C+, J Clin Pharm Ther Jun, Epub ahead of print (2 cases) (with methotrexate)
Ascites
(2016): Ben Ami E+, Expert Opin Drug Saf 15(4), 571 [REVIEW]
(2015): Cortes J+, Am J Hematol 90(4), e66
Constipation 9–16%
(2014): Linga VG+, South Asian J Cancer 3(4), 2038%
(2013): Kang YK+, Cancer Chemother Pharmacol 71(1), 432%
Diarrhea 25–59%
(2022): Kota V+, Clin Lymphoma Myeloma Leuk 22 Suppl 2, S296-S29755%
(2020): Phukan A+, Ann Hematol Oct, Online ahead of print12% (3% grade 3/4)
(2019): Abou Dalle I+, Cancer Med Sep, Epub ahead of print16%
(2019): Reichardt P+, Oncol Res Treat Sep, Epub ahead of print
(2016): Ault PS+, J Adv Pract Oncol 7(2), 16045%
(2016): Ben Ami E+, Expert Opin Drug Saf 15(4), 571 [REVIEW]45–52%
(2016): Breccia M+, Expert Opin Drug Saf 15(4), 525 [REVIEW]45%
(2016): Inayat F+, Anticancer Res 36(11), 6201>30% (passim)
(2016): Paolino G+, Cutis 97(6), e12 (passim)
(2015): Kekale M+, Patient Prefer Adherence 9, 173350%
(2015): Klein Hesselink EN+, Eur J Endocrinol 172(5), R215 [REVIEW]7%
(2014): Bauer S+, Br J Cancer 110(5), 1155 (with panobinostat)
(2014): Gambacorti-Passerini C+, Am J Hematol 89(10), 94726%
(2014): Linga VG+, South Asian J Cancer 3(4), 2039%
(2014): Serrano C+, Ther Adv Med Oncol 6(3), 115 [REVIEW]
(2014): Thota NK+, Indian J Cancer 51(1), 540%
(2013): Matti BF+, Turk J Haematol 30(4), 38719%
(2012): Radich JP+, Blood 120(19), 389841%
(2011): Khanna D+, Arthritis Rheum 63(11), 3540
(2010): Dugan E+, Anticancer Res 30 (4), 1251 (with capecitabine)
(2010): Schoffski P+, Ann Oncol 21(10), 1990 (with everolimus)
Dyspepsia / functional dyspepsia / gastroparesis
(2014): Linga VG+, South Asian J Cancer 3(4), 2038%
(2014): Thota NK+, Indian J Cancer 51(1), 513%
Gastric antral vascular ectasia (GAVE)
(2016): Abu-Amna M+, Anticancer Res 36(11), 6151-6154 (1 case / female)
(2016): Narukawa K+, Intern Med 55(1), 69-72 (3 cases)
(2016): Oshima Y+, Int J Hematol 103(5), 596-8
(2015): Ong J+, Int J Hematol 102(5), 639-42 (3 cases)
(2014): Alshehry NF+, Clin Case Rep 2(3), 77-8 (1 case)
Gastrointestinal bleeding
(2016): Banakh I+, Clin Case Rep 4(5), 486 [REVIEW]
(2015): Montagnac R+, Nephrol Ther (French) 11(6), 496
(2014): Saito M+, Rinsho Ketsueki (Japanese) 55(1), 130
Hepatotoxicity / liver injury / acute liver injury / drug-induced liver injury (DILI) 6–12%
(2018): Shah JM+, Cureus 10(4) (passim)
(2017): Osorio S+, J Oncol Pharm Pract Jan, Epub ahead of print (with sertraline)
(2017): Shahbaz O+, Expert Opin Drug Metab Toxicol 13(9), 935 [REVIEW]
(2016): Breccia M+, Expert Opin Drug Saf 15(4), 525 [REVIEW]5% (grade 3 or 4)
(2016): Lipton JH+, Lancet Oncol 17(5), 6122% (grade 3 or 4)
(2016): Turhan AG, Leuk Lymphoma 57(11), 2731 (passim)
(2016): Vincenzi B+, Expert Opin Drug Saf 15(9), 1219 [REVIEW]
(2016): Yu L+, Zhonghua Xue Ye Xue Za Zhi (Chinese) 37(7), 55410%
(2015): Egron A+, Target Oncol 10(2), 229 (2 cases)
(2015): Loue C+, J Clin Pharm Ther Jun, Epub ahead of print (2 cases) (with methotrexate)
(2014): Linga VG+, South Asian J Cancer 3(4), 2033%
(2012): Seidel C+, BMC Cancer 12(1), 186
(2010): Bilgi N+, Ann Pharmacother 44(5), 926 (with ginseng)
(2010): Tonyali O+, Med Oncol 27(3), 768
(2010): Wei G+, J Hematol Oncol 3, 47 [REVIEW]
(2007): Arai A+, Int J Hematol 86(3), 233
(2007): Kong JH+, Acta Haematol 118(4), 205
(2007): Ridruejo E+, World J Gastroenterol 13(48), 6608 (fatal) (with acetaminophen)
(2006): Cross TJ+, Am J Hematol 81(3), 189
(2006): Ikeda K+, Leuk Lymphoma 47(1), 155
Nausea 42–73%
(2022): Kota V+, Clin Lymphoma Myeloma Leuk 22 Suppl 2, S296-S29763%
(2021): Amouei A+, Int J Hematol Oncol Stem Cell Res 15(2), 114-131 [REVIEW]
(2020): Phukan A+, Ann Hematol Oct, Online ahead of print57% (1% grade 3/4)
(2019): Abou Dalle I+, Cancer Med Sep, Epub ahead of print18%
(2019): Reichardt P+, Oncol Res Treat Sep, Epub ahead of print
(2019): Zhang LQ+, Zhonghua Er Ke Za Zhi 57(2), 11323%
(2016): Ault PS+, J Adv Pract Oncol 7(2), 16050%
(2016): Ben Ami E+, Expert Opin Drug Saf 15(4), 571 [REVIEW]40–60%
(2016): Breccia M+, Expert Opin Drug Saf 15(4), 525 [REVIEW]50%
(2016): Ghunawat S+, Indian J Dermatol Venereol Leprol 82(4), 409 (passim)
(2016): Inayat F+, Anticancer Res 36(11), 6201>30% (passim)
(2016): Paolino G+, Cutis 97(6), e12 (passim)
(2015): Kekale M+, Patient Prefer Adherence 9, 173350%
(2015): Loue C+, J Clin Pharm Ther Jun, Epub ahead of print (2 cases) (with methotrexate)
(2014): Bauer S+, Br J Cancer 110(5), 1155 (with panobinostat)
(2014): Thota NK+, Indian J Cancer 51(1), 540%
(2013): Kanda T+, Int J Clin Oncol 18(1), 3839%
(2013): Kim KA+, Clin Ther 35(10), 1595 (mild / 4 cases)
(2012): Radich JP+, Blood 120(19), 389851%
(2011): Khanna D+, Arthritis Rheum 63(11), 3540
(2010): Schoffski P+, Ann Oncol 21(10), 1990 (with everolimus)
Pneumatosis intestinalis / pneumatosis cystoides intestinalis
(2014): O'Rafferty C+, Ann Hematol 93(10), 1783-4 (1 case / female)
Vomiting 23–58%
(2019): Zhang LQ+, Zhonghua Er Ke Za Zhi 57(2), 1136%
(2016): Ault PS+, J Adv Pract Oncol 7(2), 16023%
(2016): Ben Ami E+, Expert Opin Drug Saf 15(4), 571 [REVIEW]
(2016): Inayat F+, Anticancer Res 36(11), 6201>30% (passim)
(2016): Paolino G+, Cutis 97(6), e12 (passim)
(2015): Kekale M+, Patient Prefer Adherence 9, 173322%
(2015): Klein Hesselink EN+, Eur J Endocrinol 172(5), R215 [REVIEW]7%
(2014): Bauer S+, Br J Cancer 110(5), 1155 (with panobinostat)
(2014): Gambacorti-Passerini C+, Am J Hematol 89(10), 94716%
(2014): Thota NK+, Indian J Cancer 51(1), 540%
(2013): Matti BF+, Turk J Haematol 30(4), 38719%
(2012): Kantarjian HM+, Blood 119(5), 1123
(2012): Radich JP+, Blood 120(19), 389820%
(2011): Khanna D+, Arthritis Rheum 63(11), 3540
Agranulocytosis / severe selective neutropenia
(2015): Farag S+, J Clin Pharmacol 55(8), 920 [REVIEW]
Anemia
(2020): Deng M+, Medicine (Baltimore) 99(7), e19150
(2020): Phukan A+, Ann Hematol Oct, Online ahead of print90% (29% grade 3/4)
(2016): Ben Ami E+, Expert Opin Drug Saf 15(4), 571 [REVIEW]
(2016): Breccia M+, Expert Opin Drug Saf 15(4), 525 [REVIEW]4% (grade 3 or 4)
(2015): Blay JY+, Lancet Oncol 16(5), 5505% (grade 3 or 4)
(2014): Bauer S+, Br J Cancer 110(5), 1155 (with panobinostat)
(2014): Linga VG+, South Asian J Cancer 3(4), 20365%
(2014): Thota NK+, Indian J Cancer 51(1), 560%
(2013): Kang YK+, Lancet Oncol 14(12), 117529% (grade 3 or worse)
(2013): Matti BF+, Turk J Haematol 30(4), 38713% (grade 2)
(2010): Dugan E+, Anticancer Res 30 (4), 1251 (with capecitabine)
(2010): Schoffski P+, Ann Oncol 21(10), 1990 (with everolimus)
Febrile neutropenia
(2010): Hwang JE+, BMC Cancer 10, 438
(2007): Oki Y+, Cancer 109(5), 89932% (with decitabine)
Hematological adverse effect
(2021): Eskazan AE+, Clin Lymphoma Myeloma Leuk Apr, Online ahead of print (with underlying comorbidities )
Hemotoxicity
(2019): Zhang LQ+, Zhonghua Er Ke Za Zhi 57(2), 11320%
(2016): Breccia M+, Expert Opin Drug Saf 15(4), 525 [REVIEW]
(2015): Cortes J+, Am J Hematol 90(4), e66
(2013): Latagliata R+, Drugs Aging 30(8), 62919% (grade 3–4)
(2012): Radich JP+, Blood 120(19), 3898
Hypofibrinogenemia
(2019): Nair RR+, Blood Coagul Fibrinolysis 30(5), 246-248 (1 case / male)
(2018): Sciumè M+, Leuk Lymphoma 59(10), 2516-2517
Hypogammaglobulinemia
(2020): Totadri S+, Pediatr Hematol Oncol May, Epub ahead of print17%
(2008): Santachiara R+, Haematologica 93(8), 125210%
(2003): Steegmann JL+, Haematologica 88(7), 76220–25% (patients previously treated with interferon alpha)
Leukocytopenia (leukopenia) / leukocytes (white blood cells) decreased
(2014): Gambacorti-Passerini C+, Am J Hematol 89(10), 94722%
(2013): Kanda T+, Int J Clin Oncol 18(1), 3839%
(2013): Matti BF+, Turk J Haematol 30(4), 3878%
Myelosuppression / bone marrow suppression / myelotoxicity
(2009): Cortes JE+, J Clin Oncol 27(28), 4754
(2007): Oki Y+, Cancer 109(5), 899 (with decitabine)
Neutropenia (neutrophils decreased)
(2020): Phukan A+, Ann Hematol Oct, Online ahead of print75% (24% grade 3/4)
(2016): Ben Ami E+, Expert Opin Drug Saf 15(4), 571 [REVIEW]7% (grade 3 or 4)
(2016): Breccia M+, Expert Opin Drug Saf 15(4), 525 [REVIEW]17% (grade 3 or 4)
(2016): Lipton JH+, Lancet Oncol 17(5), 6128% (grade 3 or 4)
(2016): Liu Y+, J Cancer Res Ther 12 (Supplement), 23 [REVIEW]
(2015): Brummendorf TH+, Br J Haematol 168(1), 69
(2014): Gambacorti-Passerini C+, Am J Hematol 89(10), 94730%
(2014): Linga VG+, South Asian J Cancer 3(4), 20328%
(2014): Thota NK+, Indian J Cancer 51(1), 540%
(2013): Kanda T+, Int J Clin Oncol 18(1), 3840%
(2013): Kang YK+, Cancer Chemother Pharmacol 71(1), 4327%
(2013): Zhou L+, Zhonghua Xue Ye Xue Za Zhi (Chinese) 34 (2), 93
(2012): Cortes JE+, J Clin Oncol 30(28), 3486
(2010): Wei G+, J Hematol Oncol 3, 47 [REVIEW]
Pure red cell aplasia
(2016): Poudyal BS+, ESMO Open 1(3), e000058 (1 case / male)
(2010): Tanaka H+, Intern Med 49(12), 1195
Thrombocytopenia
(2020): Phukan A+, Ann Hematol Oct, Online ahead of print79% (38% grade 3/4)
(2016): Banakh I+, Clin Case Rep 4(5), 486 [REVIEW]
(2016): Ben Ami E+, Expert Opin Drug Saf 15(4), 571 [REVIEW]1% (grade 3)
(2016): Breccia M+, Expert Opin Drug Saf 15(4), 525 [REVIEW]9% (grade 3 or 4)
(2016): Gomez-Almaguer D+, Hematology 21(7), 411 (grade 4 / 1 case) (with nilotinib)
(2016): Lipton JH+, Lancet Oncol 17(5), 6127% (grade 3 or 4)
(2016): Liu Y+, J Cancer Res Ther 12 (Supplement), 23 [REVIEW]
(2014): Bauer S+, Br J Cancer 110(5), 1155 (with panobinostat)
(2014): Linga VG+, South Asian J Cancer 3(4), 20317%
(2014): Thota NK+, Indian J Cancer 51(1), 540%
(2013): Matti BF+, Turk J Haematol 30(4), 3874%
(2012): Radich JP+, Blood 120(19), 3898
Arthralgia 21–26%
(2016): Ault PS+, J Adv Pract Oncol 7(2), 16031%
(2016): Ben Ami E+, Expert Opin Drug Saf 15(4), 571 [REVIEW]
(2016): Breccia M+, Expert Opin Drug Saf 15(4), 525 [REVIEW]
(2003): Prescrire Int 12(64), 49
Asthenia / fatigue 29–75%
(2022): Kota V+, Clin Lymphoma Myeloma Leuk 22 Suppl 2, S296-S29737%
(2021): Amouei A+, Int J Hematol Oncol Stem Cell Res 15(2), 114-131 [REVIEW]
(2019): Abou Dalle I+, Cancer Med Sep, Epub ahead of print13%
(2016): Ault PS+, J Adv Pract Oncol 7(2), 16039%
(2016): Breccia M+, Expert Opin Drug Saf 15(4), 525 [REVIEW]39%
(2016): Inayat F+, Anticancer Res 36(11), 6201>30% (passim)
(2016): Wasif K+, Cureus 8(10), e848 (passim)
(2016): Yu L+, Zhonghua Xue Ye Xue Za Zhi (Chinese) 37(7), 55440%
(2015): Kekale M+, Patient Prefer Adherence 9, 173322–50%
(2014): Bauer S+, Br J Cancer 110(5), 1155 (with panobinostat)
(2014): Linga VG+, South Asian J Cancer 3(4), 20315–23%
(2014): Serrano C+, Ther Adv Med Oncol 6(3), 115 [REVIEW]
(2014): Thota NK+, Indian J Cancer 51(1), 532%
(2013): Kang YK+, Lancet Oncol 14(12), 117510% (grade 3 or worse)
(2012): Radich JP+, Blood 120(19), 389854%
(2011): Khanna D+, Arthritis Rheum 63 (11), 3540
(2010): Dugan E+, Anticancer Res 30 (4), 1251 (with capecitabine)
(2010): Schoffski P+, Ann Oncol 21(10), 1990 (with everolimus)
(2009): Cortes JE+, J Clin Oncol 27(28), 4754
(2005): Modi S+, Breast Cancer Res Treat 90(2), 15756%
(2003): Prescrire Int 12(68), 216
(2003): Verweij J+, Eur J Cancer 39(14), 200676%
(2002): Demetri GD+, N Engl J Med 347(7), 472
Bone or joint pain 11–31%
(2016): Ault PS+, J Adv Pract Oncol 7(2), 16047%
(2016): Ben Ami E+, Expert Opin Drug Saf 15(4), 571 [REVIEW]25–40%
(2016): Breccia M+, Expert Opin Drug Saf 15(4), 525 [REVIEW]31–47%
(2016): Dervis E+, Eur J Dermatol 26(2), 13312%
(2016): Inayat F+, Anticancer Res 36(11), 6201>30% (passim)
(2016): Wasif K+, Cureus 8(10), e848 (passim)
(2014): Gambacorti-Passerini C+, Am J Hematol 89(10), 94711%
(2014): Linga VG+, South Asian J Cancer 3(4), 20330%
(2014): Thota NK+, Indian J Cancer 51(1), 545%
(2013): Matti BF+, Turk J Haematol 30(4), 38736%
(2012): Cortes JE+, J Clin Oncol 30(28), 3486
(2012): Radich JP+, Blood 120(19), 389844%
(2003): Prescrire Int 12(64), 49<5%
Muscle spasm
(2022): Kota V+, Clin Lymphoma Myeloma Leuk 22 Suppl 2, S296-S29731%
(2016): Ault PS+, J Adv Pract Oncol 7(2), 16049%
(2016): Ben Ami E+, Expert Opin Drug Saf 15(4), 571 [REVIEW]
(2016): Breccia M+, Expert Opin Drug Saf 15(4), 525 [REVIEW]49%
(2016): Inayat F+, Anticancer Res 36(11), 6201>30% (passim)
(2016): Paolino G+, Cutis 97(6), e12 (passim)
(2016): Turhan AG, Leuk Lymphoma 57(11), 2731 (passim)
(2016): Wasif K+, Cureus 8(10), e848 (passim)
(2016): Yu L+, Zhonghua Xue Ye Xue Za Zhi (Chinese) 37(7), 55422%
(2014): Gambacorti-Passerini C+, Am J Hematol 89(10), 94722%
Myalgia/Myositis/Myopathy/Myotoxicity (see also necrotizing myopathy) 16–62%
(2020): Phukan A+, Ann Hematol Oct, Online ahead of print43%
(2016): Ault PS+, J Adv Pract Oncol 7(2), 16024%
(2016): Ben Ami E+, Expert Opin Drug Saf 15(4), 571 [REVIEW]
(2016): Breccia M+, Expert Opin Drug Saf 15(4), 525 [REVIEW]
(2015): Kekale M+, Patient Prefer Adherence 9, 173388%
(2014): Gambacorti-Passerini C+, Am J Hematol 89(10), 94712%
(2012): Kantarjian HM+, Blood 119(5), 1123
(2009): Cortes JE+, J Clin Oncol 27(28), 4754
(2004): Curran MP+, BioDrugs 18(3), 207 [REVIEW]
(2003): Prescrire Int 12(64), 49
(2002): Dagher R+, Clin Cancer Res 8(10), 3034
(2002): Tefferi A+, Blood 99(10), 3854
Osteonecrosis / avascular necrosis
(2017): Viviano M+, J Korean Assoc Oral Maxillofac Surg 43(2), 120 (jaw)
(2014): Mancano MA, Hosp Pharm 49(2), 121 (tibia)
(2013): Yeh CN+, J Clin Oncol 31(16), e248 (tibia)
Eyelid edema / palpebral edema / blepharedema (see also periorbital edema)
(2013): Kanda T+, Int J Clin Oncol 18(1), 3848%
(2004): Maalouf T+, J Fr Ophtalmol 27(1), 107
Optic edema
(2017): Napolitano M+, Clin Case Rep 5(10), 1573
(2013): Hager T+, Onco Targets Ther 7, 69 [REVIEW]
(2012): DeLuca C+, Optom Vis Sci 89(10), 16
Periorbital edema (see also eyelid edema) 33%
(2022): Kota V+, Clin Lymphoma Myeloma Leuk 22 Suppl 2, S296-S29735%
(2020): Teive HAG+, Arq Neuropsiquiatr 78(1), 58-59 (1 case / male)
(2019): Reichardt P+, Oncol Res Treat Sep, Epub ahead of print
(2016): Ben Ami E+, Expert Opin Drug Saf 15(4), 571 [REVIEW]
(2016): Breccia M+, Expert Opin Drug Saf 15(4), 525 [REVIEW]
(2015): Kekale M+, Patient Prefer Adherence 9, 173375%
(2014): Gambacorti-Passerini C+, Am J Hematol 89(10), 94714%
(2013): Hager T+, Onco Targets Ther 7, 69 [REVIEW]70%
(2013): Verma R+, Indian J Pharmacol 45(6), 634
(2006): Scheinfeld N, J Drugs Dermatol 5(3), 228 [REVIEW]
(2003): Fraunfelder FW+, J Ocul Pharmacol Ther 19(4), 37170%
(2003): Ramar K+, J Clin Oncol 21(1), 172
(2003): Verweij J+, Eur J Cancer 39(14), 200684%
(2002): Esmaeli B+, Cancer 95(4), 881
Hearing loss (hypoacusis)
(2016): Wasif K+, Cureus 8(10), e848
(2012): Lin HW+, Otolaryngol Head Neck Surg 146(2), 335
(2009): Janssen JJ+, Am J Hematol 84(10), 679
(2008): Attili VS+, Leuk Res 32(6), 991 [REVIEW]
Fanconi syndrome
(2016): Balak DM+, Clin Kidney J 9(1), 82 (passim)
(2008): Francois H+, Am J Kidney Dis 51(2), 298 (partial)
Nephrotoxicity / kidney injury / acute kidney injury (AKI) / drug-induced kidney injury
(2016): Breccia M+, Expert Opin Drug Saf 15(4), 525 [REVIEW]
(2012): Mulder KE+, Invest New Drugs 30(6), 2400 (with cyclosporine)
Renal failure
(2015): Loue C+, J Clin Pharm Ther Jun, Epub ahead of print (2 cases) (with methotrexate)
(2010): Gafter-Gvili A+, Leuk Res 34(1), 123
Interstitial lung disease / interstitial pneumonitis / interstitial pneumonia / drug-induced interstitial lung disease
(2019): Zhang P+, Medicine (Baltimore) 98(8) (1 case)
Pleural effusion
(2021): Su PY+, J Infect Chemother Oct, Online ahead of print (1 case / male)
(2016): Ben Ami E+, Expert Opin Drug Saf 15(4), 571 [REVIEW]
(2012): Radich JP+, Blood 120(19), 38982%
(2011): Barber NA+, Target Oncol 6(4), 235 [REVIEW]
Pneumonitis 4–13%
(2017): Luo ZB+, Turk J Haematol 34(4), 362
(2010): Stakhina OV+, Ter Arkh 82 (2), 59 (interstitial)
Pulmonary toxicity
(2015): Lee NR+, Korean J Intern Med 30(4), 550
(2011): Barber NA+, Target Oncol 6(4), 235 [REVIEW]
Adverse effects / adverse reactions
(2022): Adattini JA+, Pharmacol Res Perspect 10(5), e01005
(2016): Dervis E+, Eur J Dermatol 26(2), 13314% (cutaneous)
(2016): Lee WJ+, Int J Dermatol 55(5), e26837% (grade 3) (cutaneous)
(2016): Yu L+, Zhonghua Xue Ye Xue Za Zhi (Chinese) 37(7), 55435% (gastrointestinal)
(2015): Belum VR+, Pediatr Blood Cancer 62(5), 798 (dermatologic)
(2015): Frost AE+, J Heart Lung Transplant 34(11), 136631%
(2015): Yuan A+, Oral Oncol 51(11), 1026 (oral)
(2014): Egron A+, Target Oncol 10(2), 229
(2014): Guerin A+, Curr Med Res Opin 30(11), 2317
(2014): Saavedra D+, Leuk Lymphoma 55(12), 281375% (non-branded formulation)
(2013): Hoeper MM+, Circulation 127(10), 112844%
(2013): Seferian A+, Eur Respir Rev 22(129), 217
(2013): Thielen N+, Ann Hematol 92(8), 1049 (high-dose / with cytarabine)
(2013): Verma R+, Indian J Pharmacol 45(6), 6345% (severe)
(2012): Sibaud V+, Ann Chir Plast Esthet 57(2), 106
Death
(2011): Toubert ME+, Thyroid 21(4), 451 (with sorafenib)
(2009): Roszkiewicz F+, Pharmacology 84(1), 38 (with dasatinib)
(2007): Ridruejo E+, World J Gastroenterol 13(48), 6608 (with acetaminophen)
Side effects
(2016): Caldemeyer L+, Curr Hematol Malig Rep 11(2), 71 [REVIEW]
(2011): Amitay-Laish I+, Dermatol Ther 24(4), 386 [REVIEW] (cutaneous)
Click on the DRUG REVIEW ARTICLE tab (above) to see a review of imatinib in the Taylor & Francis journal Expert Opinion on Drug Safety. (Note that non-subscribers to the journal will only be able to see an abstract of the article.)
Adverse reactions attributed to entire drug class Antineoplastic / anticancer agent (see also Immune checkpoint inhibitor)
Flagellate dermatitis
(2022): Constantinou A+, Skin Health Dis 2(1), e92 [REVIEW] (54 cases)
Hyperkeratosis
(2020): Vastarella M+, Drug Saf Jan, Epub ahead of print [REVIEW]
Alopecia / hair loss
(2022): Hrin ML+, J Am Acad Dermatol 86(6), 1434-1435 [REVIEW]
(2018): Dunnill CJ+, Oncologist 23(1), 84-96
(2011): Miteva M+, Am J Dermatopathol 33(4), 345-50 (10 cases)
Burning Mouth Syndrome / glossodynia / glossalgia / glossopyrosis (also includes stomatodynia / oral dysesthesia / stomatopyrosis)
(2021): Hino S+, Ann Maxillofac Surg 11(1), 86-90 (15 cases)
Ulcerative stomatitis
(2021): Satheeshkumar PS+, Int J Med Inform Aug, Online ahead of print [REVIEW]
Bradycardia / sinus bradycardia
(2022): Tamargo J+, Drug Saf Jan, Online ahead of print [REVIEW]
Capillary leak syndrome
(2022): Izzedine H+, Kidney Int Rep 7(5), 945-953 [REVIEW]
Anosmia (smell loss) / smell disorder (see also hyposmia)
(2023): Debbaneh P+, Auris Nasus Larynx Jan, Online ahead of print (association)
Dysgeusia (taste perversion)
(2021): Hino S+, Ann Maxillofac Surg 11(1), 86-90 (12 cases)
Peripheral neuropathy
(2022): Tay N+, Front Mol Biosci Oct, eCollection [REVIEW]
(2021): Hino S+, Ann Maxillofac Surg 11(1), 86-90 (13 cases)
(2021): Hung HW+, Int J Environ Res Public Health 18(11), 5677
(2021): Inoue M+, Sci Rep 11(1), 11324 [REVIEW]
(2021): Li T+, Neurol Sci 42(10), 4109-4121 [REVIEW]
(2021): Selvy M+, Support Care Cancer 29(7), 4033-4043
(2011): Balayssac D+, Expert Opin Drug Saf 10(3), 407-17 [REVIEW]
Hypothyroidism
(2022): Deligiorgi MV+, Expert Rev Clin Pharmacol Jun, Online ahead of print [REVIEW]
Diarrhea
(2022): Okunaka M+, Int J Mol Sci 23(20), 12407
Esophagitis
(2022): Abdi S+, Gastroenterol Hepatol Bed Bench 15(3), 219-224 [REVIEW]
Gastrointestinal adverse reaction
(2022): Akbarali HI+, Adv Cancer Res 155, 131-166 [REVIEW]
(2021): Kawasumi K+, Mol Clin Oncol 14(1), 12
Hepatotoxicity / liver injury / acute liver injury / drug-induced liver injury (DILI)
(2022): Sanguanboonyaphong P+, Asian Pac J Cancer Prev 23(1), 93-100
(2021): Kong X+, Br J Clin Pharmacol May, Online ahead of print [REVIEW]
Nausea
(2022): Sanguanboonyaphong P+, Asian Pac J Cancer Prev 23(1), 93-100
Pneumatosis intestinalis / pneumatosis cystoides intestinalis
(2022): Gazzaniga G+, Cancers (Basel) 14(7), 1666 [REVIEW]
Vomiting
(2022): Sanguanboonyaphong P+, Asian Pac J Cancer Prev 23(1), 93-100
Anemia
(2022): Sanguanboonyaphong P+, Asian Pac J Cancer Prev 23(1), 93-100
Neutropenia (neutrophils decreased)
(2022): Sanguanboonyaphong P+, Asian Pac J Cancer Prev 23(1), 93-100
Thrombocytopenia
(2022): Sanguanboonyaphong P+, Asian Pac J Cancer Prev 23(1), 93-100
Corneal neuropathic changes
(2021): Chiang JCB+, Ocul Surf 21, 221-237 [REVIEW]
Ocular adverse effect
(2022): Sakellakis M+, Cureus 14(7), e27266 [REVIEW]
Nephrotoxicity / kidney injury / acute kidney injury (AKI) / drug-induced kidney injury
(2022): Rey A+, Fundam Clin Pharmacol Jan, Online ahead of print
Interstitial lung disease / interstitial pneumonitis / interstitial pneumonia / drug-induced interstitial lung disease
(2022): Zhonghua Zhong Liu Za Zhi (Chinese) 44(7), 693-702 [REVIEW]
(2022): Conte P+, ESMO Open 7(2), 100404
(2022): Miyagahara T+, Asia Pac J Clin Oncol Dec, Online ahead of print6%
Adverse effects / adverse reactions
(2022): Yan YD+, EClinicalMedicine Aug, eCollection [REVIEW]
(2021): Kawasumi K+, Mol Clin Oncol 14(1), 12
Tooth disorder
(2005): Tredwin CJ+, J Dent Res 84(7), 596-602 [REVIEW]
Toothache (odontalgia)
(2021): Hino S+, Ann Maxillofac Surg 11(1), 86-90 (6 cases)
(2010): Zadik Y+, J Endod 36(9), 1588-92
Adverse reactions attributed to entire drug class Biologic
Bullous pemphigoid / pemphigoid
(2022): Husein-ElAhmed H+, J Dermatolog Treat Jun, Online ahead of print [REVIEW] (15 cases)
Leukocytoclastic vasculitis (angiitis)
(2022): da Silva Cendon Duran C+, Arch Rheumatol 37(2), 300-310 [REVIEW]
Psoriasis
(2020): Afach S+, Br J Dermatol May, Online ahead of print [REVIEW]
(2020): Montolio Chiva L+, Reumatol Clin Mar, Epub ahead of print [REVIEW]
Vasculitis (angiitis) / cutaneous vasculitis (angiitis)
(2016): Gutierrez-Gonzalez LA, Curr Rheumatol Rep 18(7), 39 [REVIEW]
Hepatotoxicity / liver injury / acute liver injury / drug-induced liver injury (DILI)
(2021): Jee A+, Int J Mol Sci 22(6), 2954 [REVIEW]
Infusion-related reactions
(2016): Al-Mayouf SM+, Int J Rheum Dis 19(6), 60034%
Uveitis / anterior uveitis / posterior uveitis / panuveitis
(2020): Klein A+, ACR Open Rheumatol 2(1), 376%
Adverse effects / adverse reactions
(2020): Iannone LF+, PLoS One 15(11), eCollection
(2020): Roberti R+, Curr Med Res Opin Jun, Online ahead of print
(2016): Al-Mayouf SM+, Int J Rheum Dis 19(6), 60035%
Infection
(2020): Klein A+, ACR Open Rheumatol 2(1), 373%
Adverse reactions attributed to entire drug class Tyrosine kinase inhibitor
Cutaneous adverse reaction (includes severe cutaneous adverse drug reaction (SCAR))
(2022): Barbieri MA+, Front Oncol Nov, eCollection58%
(2019): Clapes V+, Pharmaceut Med 33(1), 2123%
Cutaneous toxicity / skin toxicity
(2015): Macdonald JB+, J Am Acad Dermatol 72(2), 203 [REVIEW]
Edema / fluid retention (see also peripheral edema)
(2016): Yu L+, Zhonghua Xue Ye Xue Za Zhi (Chinese) 37(11), 92944%
Exanthems
(2018): Sanmartin O, Curr Probl Dermatol 53, 93
Hand–foot syndrome (palmar–plantar erythrodysesthesia)
(2018): Sanmartin O, Curr Probl Dermatol 53, 93
Ichthyosis
(2022): Park JS+, J Eur Acad Dermatol Venereol Sep, Online ahead of print [REVIEW] (association)
Pigmentation
(2016): Yu L+, Zhonghua Xue Ye Xue Za Zhi (Chinese) 37(11), 92919%
Pyoderma gangrenosum
(2022): Khoshnam-Rad N+, Anticancer Drugs 33(1), e1-e8 (15 cases)
Rash
(2016): Yu L+, Zhonghua Xue Ye Xue Za Zhi (Chinese) 37(11), 92914%
Nail disorder
(2014): Prescrire Int 23(151), 180
Arrhythmias
(2021): Cheng M+, Front Cardiovasc Med Nov, eCollection [REVIEW]
Hypertension
(2020): Gadd M+, Cancer Rep (Hoboken) Aug, e1275
(2014): Fallahi P+, Expert Opin Drug Saf 13(6), 723 [REVIEW]
Thyroiditis
(2017): Rizzo LFL+, Medicina (B Aires) 77(5), 394
Weight gain
(2016): Yu L+, Zhonghua Xue Ye Xue Za Zhi (Chinese) 37(11), 92912%
Gastrointestinal disorder / discomfort
(2022): Barbieri MA+, Front Oncol Nov, eCollection34%
(2019): Clapes V+, Pharmaceut Med 33(1), 2117%
(2016): Yu L+, Zhonghua Xue Ye Xue Za Zhi (Chinese) 37(11), 92932%
Hepatic (liver) disorder / hepatobiliary disorder / hepatic (liver) dysfunction
(2022): Barbieri MA+, Front Oncol Nov, eCollection14%
Hepatotoxicity / liver injury / acute liver injury / drug-induced liver injury (DILI)
(2019): Carretero-Gonzalez A+, Medicine (Baltimore) 98(47), e18098 (3 cases) (previous treatment with immune checkpoint inhibitors also implicated)
(2016): Yu L+, Zhonghua Xue Ye Xue Za Zhi (Chinese) 37(11), 92912%
(2015): Karczmarek-Borowska B+, Contemp Oncol (Pozn) 19(2), 87 [REVIEW]
Cytopenia
(2016): Yu L+, Zhonghua Xue Ye Xue Za Zhi (Chinese) 37(11), 9298%
Asthenia / fatigue
(2016): Yu L+, Zhonghua Xue Ye Xue Za Zhi (Chinese) 37(11), 92938%
(2014): Fallahi P+, Expert Opin Drug Saf 13(6), 723 [REVIEW]
Muscle spasm
(2016): Yamada M+, Rinsho Ketsueki 57(4), 489
(2016): Yu L+, Zhonghua Xue Ye Xue Za Zhi (Chinese) 37(11), 92919%
Respiratory disorder
(2022): Barbieri MA+, Front Oncol Nov, eCollection10%
(2019): Clapes V+, Pharmaceut Med 33(1), 2112%
Infection
(2022): Barbieri MA+, Front Oncol Nov, eCollection16%
Page last updated 10/05/2022
Symbol key
Incidence 
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Seriousness
- Hospitalization possible
- Life threatening
- Fatal
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric
